Journal
THERAPEUTIC ADVANCES IN HEMATOLOGY
Volume 4, Issue 1, Pages 59-72Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/2040620712464509
Keywords
FVIII; FVIII alloantibodies; hemophilia A; immune tolerance; inhibitors; risk factors
Categories
Ask authors/readers for more resources
Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII. Inhibitor development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and a decreased quality of life. The development of an inhibitor is the result of a complex interaction between a patient's immune system and genetic and environmental risk factors. The mainstay of treatment is the eradication of the inhibitor through immune tolerance. This review summarizes the current evidence regarding inhibitor risk factors, eradication, and hemostatic bypassing agents.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available